Cohance Lifesciences Quarterly Results
Cohance Lifesciences quarterly results. In Sept 2026, Cohance Lifesciences (COHANCE) reported revenue ₹489 Cr and net profit ₹2 Cr — revenue -14.4% YoY. For annual financials, live price and key ratios, visit Cohance Lifesciences screener.
COHANCE Quarterly Results — Revenue, Profit & EPS Highlights
Cohance Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View COHANCE 52-week performance for the annual high/low range and current price position.
- Revenue of ₹489 Cr in Sept 2026 (-20.7% vs Mar 2026, -14.4% vs Sept 2025)
- Net Profit of ₹2 Cr in Sept 2026 (-75.0% vs Mar 2026, -97.0% vs Sept 2025)
- EBITDA of ₹48 Cr in Sept 2026 (-40.0% vs Mar 2026)
- Operating Margin of 7.0% in Sept 2026 (-6.0pp vs Mar 2026)
- Earnings Per Share of ₹0.40 in Sept 2026 (-21.6% vs Mar 2026)
Cohance Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
COHANCE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 489 | 617 | 435 | 571 | 853 | -20.7% | -14.4% |
| Net Profit (₹ Cr) | 2 | 8 | -45 | 66 | 117 | - | - |
| EBITDA (₹ Cr) | 48 | 80 | 13 | 137 | 226 | - | - |
| EPS (₹) | 0.40 | 0.51 | -0.63 | 1.94 | 3.16 | - | - |
| Operating Margin (%) | 7.0% | 13.0% | 0.0% | 22.0% | 25.0% | - | - |
COHANCE Share Price Trend — 1-Year Movement Across Quarterly Results
Cohance Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Cohance Lifesciences stock price data download to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
COHANCE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cohance Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores